Search results
- Regulatory news (469) Apply Regulatory news filter
- Press releases (163) Apply Press releases filter
- Basic page (29) Apply Basic page filter
- Pipeline (19) Apply Pipeline filter
- Corporate presentations (16) Apply Corporate presentations filter
- Shareholder meeting (16) Apply Shareholder meeting filter
- Team member (15) Apply Team member filter
- Videos (14) Apply Videos filter
- Financial reports (9) Apply Financial reports filter
- Analyst (6) Apply Analyst filter
- Webcasts and audio (5) Apply Webcasts and audio filter
- Event (3) Apply Event filter
- Investor contact (3) Apply Investor contact filter
- Research (3) Apply Research filter
- Financial calendar (1) Apply Financial calendar filter
OXB–302
OXB-302
Gene-based immunotherapy targeting a range of cancers
Status: Pre–Clinical complete
OXB–201
OXB-201
Gene therapy for wet age-related macular degeneration
Status: Phase I trial complete
SAR421869 (Sanofi)
SAR421869
Gene therapy for Usher syndrome type 1B
Licensed to Sanofi: Phase I/IIa trial ongoing
LV305 (Immune Design)
LV305
This is a partner's product, where Oxford Biomedica provide process development and bioprocessing.